Get the Stockscreener App
99.41
3.67%
3.52
Rhythm Pharmaceuticals Inc stock is traded at $99.41, with a volume of 768.34K.
It is up +3.67% in the last 24 hours and down -5.50% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$95.89
Open:
$95.46
24h Volume:
768.34K
Relative Volume:
1.24
Market Cap:
$6.60B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-35.38
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-0.89%
1M Performance:
-5.50%
6M Performance:
+73.55%
1Y Performance:
+66.32%
1-Day Range:
$95.46
$102.12
1-Week Range:
$95.46
$102.70
52-Week Range:
$45.91
$116.00
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
99.41 | 6.40B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Can Rhythm Pharmaceuticals Inc. stock weather global recessionDividend Hike & Accurate Entry/Exit Alerts - newser.com
Why retail investors favor Rhythm Pharmaceuticals Inc. stockEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Will Rhythm Pharmaceuticals Inc. (1RV) stock profit from automation waveJuly 2025 WrapUp & Fast Gain Swing Alerts - newser.com
Can machine learning forecast Rhythm Pharmaceuticals Inc. recovery2025 Institutional Moves & Fast Exit and Entry Trade Guides - newser.com
What to do if you’re stuck in Rhythm Pharmaceuticals Inc.2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Is Rhythm Pharmaceuticals Inc. reversing from oversold territoryMarket Trend Report & Fast Entry Momentum Alerts - newser.com
Rhythm Pharmaceuticals at Guggenheim Conference: Strategic Insights on Obesity Treatment - Investing.com Australia
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdown2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Visualizing Rhythm Pharmaceuticals Inc. stock with heatmapsMarket Volume Report & Growth Focused Investment Plans - newser.com
Will Rhythm Pharmaceuticals Inc. price bounce be sustainable2025 Market Overview & Breakout Confirmation Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. stock positioned for digital transformationMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Canaccord Genuity Raises Price Target for RYTM Amidst Continued 'Buy' Rating | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (RYTM) Showcases Promising Obesity Drug D - GuruFocus
FDA extends review period for Rhythm’s Imcivree - The Pharma Letter
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 - The Manila Times
Rhythm Pharma (NASDAQ: RYTM) presents 27.1% BMI drop with setmelanotide plus GLP-1 - Stock Titan
How resilient is Rhythm Pharmaceuticals Inc. stock in market downturnsQuarterly Trade Review & Risk Adjusted Buy/Sell Alerts - newser.com
Rhythm pharma down as FDA extends review period for Imcivree label expansion - MSN
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million - AOL.com
Rhythm Pharmaceuticals Q3 2025 Earnings Preview - MSN
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - MSN
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target - Investing.com India
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target By Investing.com - Investing.com UK
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - 富途牛牛
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position - MSN
US FDA extends review of Rhythm's drug for brain damage-related obesity - Reuters
Rhythm Pharmaceuticals stock falls after FDA extends review period By Investing.com - Investing.com Philippines
Rhythm Pharmaceuticals stock falls after FDA extends review period - Investing.com
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event | RYTM SEC FilingForm 8-K - Stock Titan
US FDA extends review of Rhythm Pharma's drug for rare form of obesity - TradingView
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):